Hypercatecholaminaemia in stress urinary incontinence and its pathogenetic treatment perspectives: an experimental non-randomised study

Background. Urinary incontinence is associated with chronic psycho-emotional stress. Stress management should be part of a comprehensive treatment for urinary incontinence.
Objectives. An assessment of hypercatecholaminaemia severity and dynamics in repeated courses of TES therapy for stress urinary incontinence.
Methods. A total of 100 stress urinary incontinence patients were divided between a comparison and two main cohorts. Main cohort 1 (n = 30) received a modern standard treatment in combination with TES therapy. TES therapy was performed in three courses (1 session per day for 7 days): course 1 on admission, course 2 in 3 months after course 1, course 3 in 6 months after course 1. Main cohort 2 (n = 40) received a modern standard treatment in combination with two short courses of TES-therapy (2 sessions per day for 7 days): course 1 on admission, course 2 in 6 months after course 1. The comparison cohort (n = 30) only had standard treatment. Catecholamine concentrations were assessed over time in each cohort.
Results. Catecholamine concentrations were >2 times higher before treatment in all cohorts vs. healthy volunteers. The comparison cohort revealed adrenaline and noradrenaline concentrations 71.2% (p < 0.05) and 84.0% (p < 0.05) higher vs. healthy volunteers, respectively, by month 6 of the trial. Main cohort 1 had the concentrations of adrenaline and noradrenaline 2.1 (p < 0.05) and 1.5 (p < 0.05) times higher, respectively, vs. healthy volunteers. Main cohort 2 showed an adrenaline concentration 12.5% (p < 0.05) and noradrenaline — 2.4% higher (p = 0.15) vs. healthy volunteers.
Conclusion. TES therapy affects urinary incontinence hypercatecholaminaemia, demonstrating a favourable homeostatic impact on neuroimmunoendocrine regulation.

1. Sussman R.D., Syan R., Brucker B.M. Guideline of guidelines: urinary incontinence in women. BJU Int. 2020; 125(5): 638–655. DOI: 10.1111/bju.14927

2. Vaughan C.P., Markland A.D. Urinary Incontinence in Women. Ann. Intern. Med. 2020; 172(3): ITC17– ITC32. DOI: 10.7326/AITC202002040

3. Aoki Y., Brown H.W., Brubaker L., Cornu J.N., Daly J.O., Cartwright R. Urinary incontinence in women. Nat. Rev. Dis. Primers. 2017; 3: 17042. DOI: 10.1038/nrdp.2017.42

4. Balk E.M., Rofeberg V.N., Adam G.P., Kimmel H.J., Trikalinos T.A., Jeppson P.C. Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A Systematic Review and Network Meta-analysis of Clinical Outcomes. Ann. Intern. Med. 2019; 170(7): 465–479. DOI: 10.7326/M18-3227

5. Felde G., Ebbesen M.H., Hunskaar S. Anxiety and depression associated with urinary incontinence. A 10- year follow-up study from the Norwegian HUNT study (EPINCONT). Neurourol. Urodyn. 2017; 36(2): 322–328. DOI: 10.1002/nau.22921

6. Felde G., Engeland A., Hunskaar S. Urinary incontinence associated with anxiety and depression: the impact of psychotropic drugs in a cross-sectional study from the Norwegian HUNT study. BMC Psychiatry. 2020; 20(1): 521. DOI: 10.1186/s12888-020-02922-4

7. Kade A.K., Akhedzhak-Naguze S.K. The change in stress resistance of the students when applying transcranial electrostimulation. Kuban Scientific Medical Bulletin. 2018; 25(2): 78–81 (In Russ., English abstract). DOI: 10.25207/1608-6228-2018-25-2-78-81

8. O’Connor E., Nic An Riogh A., Karavitakis M., Monagas S., Nambiar A. Diagnosis and Non-Surgical Management of Urinary Incontinence — A Literature Review with Recommendations for Practice. Int. J. Gen. Med. 2021; 14: 4555–4565. DOI: 10.2147/IJGM.S289314

9. van der Hoorn F.A., Boomsma F., Man in ‘t Veld A.J., Schalekamp M.A. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J. Chromatogr. 1989; 487(1): 17–28. DOI: 10.1016/s0378-4347(00)83003-0

10. Mizutani H., Sakakibara F., Komuro M., Sasaki E. TAS-303, a Novel Selective Norepinephrine Reuptake Inhibitor that Increases Urethral Pressure in Rats, Indicating Its Potential as a Therapeutic Agent for Stress Urinary Incontinence. J. Pharmacol. Exp. Ther. 2018; 366(2): 322–331. DOI: 10.1124/jpet.118.248039

11. Sanford M.T., Rodriguez L.V. The role of environmental stress on lower urinary tract symptoms. Curr. Opin. Urol. 2017; 27(3): 268–273. DOI: 10.1097/MOU.0000000000000379

12. Mills K.A., West E.G., Sellers D.J., Chess-Williams R., McDermott C. Psychological stress induced bladder overactivity in female mice is associated with enhanced afferent nerve activity. Sci. Rep. 2021; 11(1): 17508. DOI: 10.1038/s41598-021-97053-5

13. Fioranelli M., Bottaccioli A.G., Bottaccioli F., Bianchi M., Rovesti M., Roccia M.G. Stress and Inflammation in Coronary Artery Disease: A Review Psychoneuroendocrineimmunology-Based. Front. Immunol. 2018; 9: 2031. DOI: 10.3389/fimmu.2018.02031

14. Kupper N., Denollet J. Type D. Personality as a Risk Factor in Coronary Heart Disease: a Review of Current Evidence. Curr. Cardiol. Rep. 2018; 20(11): 104. DOI: 10.1007/s11886-018-1048-x

15. Böhm M., Reil J.C., Deedwania P., Kim J.B., Borer J.S. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. Am. J. Med. 2015; 128(3): 219–228. DOI: 10.1016/j.amjmed.2014.09.016

16. Kraus C., Kadriu B., Lanzenberger R., Zarate C.A. Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl. Psychiatry. 2019; 9(1): 127. DOI: 10.1038/s41398-019-0460-3